Main functions of liver includes removing harmful substances from blood, storing nutrients and vitamins, maintaining proper balance of chemical levels in the body. Diseases which cause improper functioning of liver are termed as liver diseases. There are various liver diseases that ultimately lead to liver failure i.e. permanent damage of liver cells. Some of the commonly occurred liver diseases are hepatitis B, hepatitis C, hemochromatosis and liver cirrhosis.
Common symptoms of liver disease include, fatigue, nausea, sudden weight loss, swollen abdomen and jaundice (yellow discoloration of skin). The prevalence of liver diseases is high in developed countries compared to developing countries. Sedentary lifestyle, obesity, viral hepatitis, genetic disorders, unhealthy diet, and excessive alcohol consumption are some of the factors that are fueling the growth liver disease prevalence in developing countries. Thus, rising prevalence of liver diseases globally is primarily driving the liver disease treatment market towards growth. Furthermore, the treatment for hepatitis is the major segment of liver disease treatment market and has potential to grow at a faster pace due to increased incidence of hepatitis C in developing countries. Based on the drugs class, the global liver disease treatment market can been segmented as follows:
- Immune globulins targeted therapy
- Immunosuppressive agents
- Anabolic steroids
- Alcohol abuse drugs
- Anti rejection drugs
- Infection fighting drug
- Antifungal prophylaxis
- Gallstone solubilizing agents
Regionally, the global liver disease treatment market has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). North America comprises cumulative liver disease treatment market for the U.S and Canada. Europe comprises cumulative market of liver disease treatment in Germany, Italy, France, Spain, and Rest of Europe (RoE). Asia Pacific comprises cumulative market of liver disease treatment in China, India, Australia, New Zealand and rest of Asia Pacific (RoAPAC). Rest of the World (RoW) comprises liver disease treatment market in Latin America, Middle East and Russia. North America commands the largest share of the global liver disease treatment market and is closely followed by Europe. Developed regulatory framework, reimbursement coverage and higher healthcare spending are some of the factors that are driving the growth of liver disease treatment market in North America and Europe. Asia Pacific market is anticipated to show significant growth during the forecast period owing to growing medical tourism industry coupled with rising prevalence of liver disease in this region. In addition, increasing disposable income and improving healthcare infrastructure are some of the other factors that are supporting the growth of liver disease treatment market in Asia Pacific. Latin American countries such as Mexico, Argentina and Brazil are expected to enormous growth compared to other countries in this region. Presence of highly developed healthcare infrastructure coupled with relatively higher healthcare spending are some of the factors that are anticipated to propel the growth of liver disease treatment market in Latin America.
The major players in the liver diseases treatment market include Abbott Laboratories, Bayer Schering Ag, Bristol-Myers Squibb, Eli Lilly, Merck & Co., Novartis, Pfizer, Roche, Sanofi-Aventis, Takeda Pharmaceutical, and Zydus Pharmaceuticals Inc. The report analyses the global scenario of liver disease treatment market and further includes detailed overview and market figures. The research report analyses the industry growth rate, industry capacity, and industry structure. The report analyses the historical data and forecasts the liver disease treatment market size, production forecasts along with key factors driving and restraining the market.
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.